PET/CT imaging of somatostatin receptor expressing solid tumors with the novel somatotostatin receptor antagonist 68Ga-NODAGA-LM3
Conclusion: PET/CT imaging with the SSR-antagonist 68Ga-NODAGA-LM3 demonstrated excellent image quality with high specific uptake in SSR-expressing lesions. Despite the limited number of patients for direct comparison with 68Ga-DOTATOC, 68Ga-NODAGA-LM3 detected more SSR-expressing lesions, which adheres to the recently reported results comparing radiolabeled SSR-antagonists with agonists. Compared to the agonists, it also provides a significant advantage of detecting more lesions in the liver due to the distinctively higher tumor-to-liver ratio. The results emphasize the potential of the SSR-antagonist 68Ga-NODAGA-LM3 for PET/CT imaging of SSR-expressing solid tumors in humans.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: SINGH, A., Kulkarni, H., Langbein, T., Mueller, D., Senftleben, S., Fani, M., Maecke, H., Baum, R. Tags: Somatostatin Receptor Imaging Source Type: research
More News: Acetic Acid | Brain | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Kidney Cancer | Liver | Liver Cancer | Men | Neurology | Nuclear Medicine | Pancreas | Pancreatic Cancer | Paraganglioma | Pheochromocytoma | Renal Cell Carcinoma | Splenectomy | Study | Thyroid | Thyroid Cancer | Urology & Nephrology